Non-Hodgkin lymphoma

非霍奇金淋巴瘤
  • 文章类型: Journal Article
    背景:滤泡性淋巴瘤是一种常见的非霍奇金淋巴瘤,可以在整个身体的各种组织中开始。虽然大多数患者可能患有这种疾病,治愈仍然很难实现。
    目的:我们试图利用一个大型国家数据库研究早期滤泡性淋巴瘤原发部位对患者预后的影响。
    方法:从NCI监测中确定并提取了2000-2015年诊断为滤泡性淋巴瘤的患者的基线人口统计学和疾病数据。流行病学,和结束结果(SEER)数据库。原发疾病部位分为两个队列之一:淋巴结疾病(淋巴结和脾脏)和结外疾病(其他所有疾病)。使用汇总统计进行分析,Kaplan-Meier方法,以及用于单变量和多变量分析的Cox比例风险模型。
    结果:最终分析共纳入13,400名患者,其中大部分是非西班牙裔白人(81%),第一阶段(63%),和节点FL(79%)。结节性疾病的中位总生存期为15.1年[95%CI(14.6-15.6)],而结外疾病的中位总生存期为15.8年[95%CI(14.9-16.3)]。结外疾病患者的总生存期略好[HR=0.89,95%CI(0.84-0.96);p值=0.00012]。在控制年龄和种族后,这一发现保持一致[HR=0.84,95%CI(0.79-0.90);p值<0.0001]。
    结论:早期滤泡性淋巴瘤的主要受累部位可能对患者预后有影响,值得进一步研究。
    BACKGROUND: Follicular lymphoma is a common non-Hodgkin lymphoma that can start in a diverse array of tissues throughout the body. While the majority of patients may be able to live many years with this disease, cure remains very difficult to achieve.
    OBJECTIVE: We sought to investigate the impact of follicular lymphoma primary disease site in early-stage disease on patient outcomes using a large national database.
    METHODS: Baseline demographic and disease data for patients diagnosed with follicular lymphoma from 2000-2015 was identified and extracted from the NCI Surveillance, Epidemiology, and End Results (SEER) database. Primary disease sites were grouped into one of two cohorts: nodal disease (lymph nodes and spleen) and extranodal disease (everything else). Analysis was performed using summary statistics, Kaplan-Meier method, and Cox-proportional hazards models for univariate and multivariate analysis.
    RESULTS: A total of 13,400 patients were included in the final analysis and the majority were non-Hispanic white (81%), with stage I (63%), and nodal FL (79%). Median overall survival for nodal disease was 15.1 years [95% CI (14.6-15.6)] while median overall survival for extranodal disease was 15.8 years [95% CI (14.9-16.3)]. Overall survival was slightly better for patients with extranodal disease [HR = 0.89, 95% CI (0.84-0.96); p-value = 0.00012]. This finding remained consistent after controlling for age and race [HR = 0.84, 95% CI (0.79-0.90); p-value <0.0001].
    CONCLUSIONS: The primary site of involvement by early-stage follicular lymphoma may have an impact on patient outcomes and warrants further investigation.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:非霍奇金淋巴瘤(NHL)已被确定为癌症负担的重要原因。这项研究调查了发病率,死亡率,2011年至2020年文莱达鲁萨兰国NHL癌症的生存趋势。
    方法:这是一项基于注册的回顾性研究,使用文莱达鲁萨兰国癌症注册中心的去识别数据,根据ICD-10代码C82-86,对2011年至2020年诊断为NHL的患者进行研究。统计方法包括描述性统计,年龄特异性和年龄标准化发病率(ASIR)和死亡率(ASMR),和用于趋势分析的连接点回归。使用Kaplan-Meier图进行生存分析,对数秩检验,和Cox比例风险回归。
    结果:从2011年到2020年,330例患者被诊断为NHL。大多数患者是男性(51.8%)和马来人后裔(82.7%)。诊断最多的年龄组为55-74岁(42.3%),诊断时的平均年龄为55.1岁。男性ASIR为12.12,女性为10.39/100,000;男性ASMR为6.11,女性为4.76/100,000。弥漫性大B细胞淋巴瘤是最常见的亚型,占病例数的39.1%。5年生存率为61.2%,在老年患者和远处转移阶段诊断的患者中观察到较低的发生率。此外,高龄和晚期诊断显著增加死亡风险.文莱达鲁萨兰国的NHL发病率和死亡率在10年内保持稳定,但突出了性别和年龄的显著差异。
    结论:研究结果强调了早期发现和定制治疗的重要性,尤其是高危人群,管理NHL的负担。这些见解强调了需要有针对性的医疗保健策略和持续的研究来解决NHL的挑战。
    BACKGROUND: Non-Hodgkin lymphoma (NHL) has been identified as a significant contributor to the cancer burden. This study investigates the incidence, mortality, and survival trends of NHL cancer in Brunei Darussalam from 2011 to 2020.
    METHODS: This is a registry-based retrospective study using de-identified data from the Brunei Darussalam Cancer Registry on patients diagnosed with NHL from 2011 to 2020 based on the ICD-10 codes C82-86. Statistical methods include descriptive statistics, age-specific and age-standardised incidence (ASIR) and mortality rates (ASMR), and joinpoint regression for trend analysis. Survival analysis was conducted using Kaplan-Meier plots, log-rank test, and Cox Proportional Hazards regression.
    RESULTS: From 2011 to 2020, 330 patients were diagnosed with NHL. The majority of patients were males (51.8%) and of Malay descent (82.7%). The age group most diagnosed was 55-74 years (42.3%), with a mean age at diagnosis being 55.1 years. The ASIRs were 12.12 for males and 10.39 per 100,000 for females; ASMRs were 6.11 for males and 4.76 per 100,000 for females. Diffuse large B-cell lymphoma was the most prevalent subtype, accounting for 39.1% of cases. The overall 5-year survival rate was 61.2%, with lower rates observed in older patients and those diagnosed at distant metastasis stage. Furthermore, older age and advanced stage diagnosis significantly increased mortality risk. NHL incidence and mortality rates in Brunei Darussalam remain stable over the period of 10 years, but highlights significant disparities in gender and age.
    CONCLUSIONS: The findings emphasize the importance of early detection and tailored treatments, especially for high-risk groups, in managing NHL\'s burden. These insights underline the need for focused healthcare strategies and continued research to address NHL\'s challenges.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    尚未系统地收集有关淋巴瘤患者特征的具体数据,而非霍奇金淋巴瘤(NHL)被确定为第7位最常见的癌症,霍奇金淋巴瘤(HL)是第28位。炎症在淋巴瘤的发病和进展中起着重要作用。营养不良是淋巴瘤的不良预后因素。全身炎症指数(SII),预后营养指数(PNI),和晚期肺癌炎症指数(ALI)是描述炎症和营养状况的生物标志物。本研究旨在描述HL和NHL患者的临床和生物标志物特征。
    这项描述性研究使用了横截面设计,数据来自2020年1月至2023年11月HasanSadikin医院淋巴瘤登记处。人口统计,分期,并提取组织病理学数据。评估了三种生物标志物。使用Kaplan-Meier曲线分析绘制生存曲线,采用对数秩检验比较早期和晚期的生存率。
    共招募了271名患者作为参与者,大多数(80.5%)患有NHL,弥漫性大B细胞淋巴瘤(DLBCL)是最常见的组织病理学类型(50.5%)。在三分之二的患者中观察到早期疾病,低危国际预后指数(IPI)评分是最常见的预后评分(95%).与晚期相比,早期的SII略高。对101例患者的治疗反应进行了评估,并观察到44.5%的完全缓解。2年总生存率(OS)为93.1%,中位生存期为22.7个月(95%CI21.9-23.5个月)。在早期阶段,中位生存期略长于晚期[23.0(95%CI22.2-23.8)vs21.6(95%CI19.3-23.8)个月,P=0.09]。
    霍奇金淋巴瘤和DLBCL具有相似的临床和生物标志物特征。三种生物标志物SII之间有轻微差异,ALI,和基于疾病阶段的PNI。几乎所有患者在2年的随访中仍然存活。
    UNASSIGNED: No specific data have been systematically collected regarding lymphoma patient characteristics, while non-Hodgkin lymphoma (NHL) is identified as the 7th most common cancer and Hodgkin lymphoma (HL) is the 28th. Inflammation plays an important role in the pathogenesis and progression of lymphoma. Malnutrition is an adverse prognostic factor in lymphoma. Systemic Inflammatory Index (SII), Prognostic Nutritional Index (PNI), and Advanced Lung Cancer Inflammation Index (ALI) were biomarkers depicting inflammation and nutritional status. This study aims to describe the clinical and biomarker characteristics of both HL and NHL patients.
    UNASSIGNED: This descriptive study used a cross-sectional design, and data were collected from Hasan Sadikin Hospital lymphoma registry from January 2020 to November 2023. Demographic, staging, and histopathological data were extracted. Three biomarkers were evaluated. Survival curves were drawn using Kaplan-Meier curve analysis, and the log rank test was used for comparison of survival between early and advanced stage.
    UNASSIGNED: A total of 271 patients were recruited as participants, and the majority (80.5%) had NHL, with diffuse large B-cell lymphoma (DLBCL) being the most common histopathological type (50.5%). Early disease was observed in two-thirds of patients, and low-risk International Prognostic Index (IPI) score was the most common prognostic score found (95%). SII was slightly higher in early compared to advanced stages. Treatment response was evaluated from 101 patients, and complete response was observed in 44.5%. Two-year overall survival (OS) was 93.1%, with median survival 22.7 (95% CI 21.9-23.5) months. In early stage, the median survival was slightly longer than in advanced stage [23.0 (95% CI 22.2-23.8) vs 21.6 (95% CI 19.3-23.8) months, P=0.09].
    UNASSIGNED: Hodgkin lymphoma and DLBCL had similar clinical and biomarker characteristics. There were slight differences between the three biomarkers SII, ALI, and PNI based on the disease stage. Almost all patients still survived at 2-year follow-up.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    第二原发性恶性肿瘤的发生在癌症幸存者中变得越来越重要。黑色素瘤,一种起源于黑素细胞的侵袭性肿瘤,是大多数皮肤癌相关死亡的原因。这篇综述旨在探讨黑色素瘤作为最常见的血液肿瘤亚型之后的第二原发癌的发生风险。起源于髓系或淋巴细胞谱系的恶性疾病。慢性淋巴细胞白血病(CLL)和非霍奇金淋巴瘤(NHL)是与黑色素瘤发展最相关的亚型之一。我们还讨论了可能解释这些恶性肿瘤与黑色素瘤对生存影响之间关联的潜在假设。该综述强调了提高血液肿瘤幸存者对黑色素瘤风险认识的重要性。因为它可以导致迅速的识别,改善皮肤监测,和更好的生存结果。
    The occurrence of second primary malignancies is becoming increasingly important among cancer survivors. Melanoma, an aggressive neoplasm originating from the melanocytes, is responsible for most skin cancer-related deaths. This review aims to explore the risk of melanoma occurrence as a second primary cancer after the most common subtypes of hematologic neoplasia, a malignant disease originating from myeloid or lymphocytic cell lineages. Chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) are among the most associated subtypes with melanoma development. We also discuss the underlying hypotheses that may explain the associations between these malignancies and the impact of melanoma on survival. The review emphasizes the importance of increasing awareness of melanoma risk in hematologic cancer survivors, as it can lead to prompt recognition, improved skin surveillance, and better survival outcomes.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    血液恶性肿瘤(HM)是众所周知的坏疽性脓皮病(PG)的潜在合并症。然而,量化HMs后PG可能性的研究尚未进行。
    为了研究PG和几个HM之间的双向关联,即急性白血病,慢性白血病,霍奇金淋巴瘤,非霍奇金淋巴瘤,和多发性骨髓瘤.
    进行了一项基于人群的回顾性队列研究,以研究PG(n=302)患者的HMs风险与年龄,性别和种族匹配的对照受试者(n=1,799)。使用病例对照设计来估计先前有HMs病史的个体中PG的可能性。通过Cox回归和逻辑回归来估计调整后的风险比(HRs)和调整后的比值比(ORs)。分别。
    PG患者先前存在的HM的患病率高于对照组(6.7%vs.0.9%,分别)。在有HM病史的患者中,患PG的可能性明显更大(调整后的OR,7.88;95%CI,3.85-16.15;p<0.001),特别是在诊断后的第一年。这种关联对急性白血病很重要,慢性白血病,非霍奇金淋巴瘤,和多发性骨髓瘤,但不是霍奇金淋巴瘤。在PG患者和对照组中,HM的发生率为3.3(95%CI,1.2-7.4)和1.6(95%CI,0.9-2.6)/1,000人年,分别。相对于控件,PG患者不太可能发生后续HM(调整后的HR,2.22;95CI,0.77-6.45;p=0.142)。与其他PG患者相比,患有HM相关PG的患者全因死亡率增加(调整后的HR,2.19;95CI,1.09-4.40;p=0.028)。
    HM,特别是急性白血病和多发性骨髓瘤,与引发PG的可能性增加有关。
    UNASSIGNED: Hematologic malignancies (HMs) are well-known underlying comorbidities of pyoderma gangrenosum (PG). However, studies quantifying the likelihood of PG after HMs are yet to be performed.
    UNASSIGNED: To investigate the bidirectional association between PG and several HMs, namely acute leukemia, chronic leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma, and multiple myeloma.
    UNASSIGNED: A population-based retrospective cohort study was conducted to study the risk of HMs in patients with PG (n = 302) as compared to age-, sex-and ethnicity-matched control subjects (n = 1,799). A case-control design was used to estimate the likelihood of PG in individuals with a preexisting history of HMs. Adjusted hazard ratios (HRs) and adjusted odds ratios (ORs) were estimated by Cox regression and logistic regression, respectively.
    UNASSIGNED: The prevalence of preexisting HM was higher in patients with PG than in controls (6.7% vs. 0.9%, respectively). The likelihood of having PG was significantly greater among patients with a history of HM (adjusted OR, 7.88; 95% CI, 3.85-16.15; p < 0.001), particularly during the first year following the diagnosis. This association was significant for acute leukemia, chronic leukemia, non-Hodgkin lymphoma, and multiple myeloma but not for Hodgkin lymphoma. The incidence rate of HM was 3.3 (95% CI, 1.2-7.4) and 1.6 (95% CI, 0.9-2.6)/1,000 person-years among patients with PG and controls, respectively. Relative to controls, patients with PG were not more likely to develop subsequent HM (adjusted HR, 2.22; 95%CI, 0.77-6.45; p = 0.142). Compared to other patients with PG, those with HM-associated PG experienced an increased all-cause mortality rate (adjusted HR, 2.19; 95%CI, 1.09-4.40; p = 0.028).
    UNASSIGNED: HM, particularly acute leukemia and multiple myeloma, are associated with an elevated likelihood of provoking PG.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Case Reports
    背景:“包虫囊肿”或囊性棘球蚴病是由细粒棘球蚴幼虫期引起的寄生虫感染。肝脏和肺是最常见的发生部位。肌肉的发病率非常罕见。手术一直是治疗囊性包虫病的传统方法。
    方法:我们报告了一例罕见的44岁男性多发性包虫囊肿;肺,椎旁肌肉.肌肉囊肿表现为背部肿胀,是主要的临床表现,因为它引起疼痛和不适。他接受了阿苯达唑治疗,并进行了治疗肺囊肿的胸外科手术。入院时和手术后,已经出现淋巴结病,经过适当的诊断方法,他被诊断为非霍奇金淋巴瘤.然后,三个月后,体格检查显示,他的背部囊肿的大小明显减少,不再可见。
    结论:这里我们提出了一种成功治疗肌肉包虫囊肿的方法。虽然以前的报道已经通过手术治疗;阿苯达唑在我们的病例中发挥了重要作用,除了在治疗多个包虫囊肿的过程中诊断NHL。
    结论:非霍奇金淋巴瘤合并肝囊性疾病的情况很少见,NHL和肌肉包虫病的共存在医学文献中是前所未有的。
    BACKGROUND: \"Hydatid cyst\" or cystic Echinococcosis is a parasitic infection caused by the larval stage of Echinococcus granulosus. The liver and lungs are the most common sites to occur. Incidence in muscles is exceptionally rare. Surgery has been the traditional approach for treatment of cystic echinococcusis.
    METHODS: We report a rare case of 44 years old man with multiple hydatid cysts; liver, lungs, paraspinal muscles. The muscular cyst had manifested as a swelling in his back and was the principal clinical presentation as it caused pain and discomfort. He was treated with Albendazole, and a thoracic surgery for the management of the lung cysts had been performed. On admission and after his surgery, lymphadenopathy had manifested and following adequate diagnostic modalities he was diagnosed with Non-Hodgkin lymphoma. Then, after three months, physical examination revealed significant reduction in the size of his back cyst that was no longer visible.
    CONCLUSIONS: Here we present a successful treatment for muscular hydatid cysts. While prior reports have managed it surgically; albendazole has played a significant role in our case, in addition to the diagnosis of the NHL in the course of managing multiple hydatid cysts.
    CONCLUSIONS: The presence of non-Hodgkin lymphoma alongside hepatic cystic disease is rare, and the coexistence of NHL and muscular hydatidosis is unprecedented in medical literature.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    这项研究的目的是分析1990年至2019年中国非霍奇金淋巴瘤发病率和死亡率的趋势,并评估年龄的影响。period,和队列,预测未来趋势。
    使用2019年全球疾病负担研究的数据,我们计算了非霍奇金淋巴瘤发病率和死亡率的估计年度百分比变化。使用年龄周期队列分析来评估这些元素的独立影响。到2030年的发病率和死亡率是使用贝叶斯年龄时期队列方法预测的。
    在1990-2019年期间,非霍奇金淋巴瘤的年龄标准化发病率和死亡率显着增加。观察到出生队列和时期对非霍奇金淋巴瘤发病率和死亡率的强烈影响。在预测方面,未来非霍奇金淋巴瘤在中国的发病率和死亡率将继续增加,而死亡率将会下降;对于女性来说,两者的利率预计都会上升,但他们会比男人低。
    目前,中国的非霍奇金淋巴瘤负担很高,预计未来还会继续增加。政策制定者需要优先解决导致疾病负担性别差异的因素,包括男女环境暴露和生活方式的变化。
    UNASSIGNED: The aim of this study was to analyze the trend of non-Hodgkin\'s lymphoma incidence and mortality in China from 1990 to 2019, along with assessing the effects of age, period, and cohort, as well as to predict future trends.
    UNASSIGNED: Using data from the Global Burden of Disease Study 2019 we calculated the estimated annual percentage changes in the incidence and mortality of non-Hodgkin\'s lymphoma. Age-period-cohort analysis was used to assess the independent effects of these elements. Incidence and mortality until 2030 were predicted using a Bayesian age-period-cohort approach.
    UNASSIGNED: During 1990-2019, there was a significant increase in the age-standardized incidence and mortality rate in non-Hodgkin\'s lymphoma. Strong effects of birth cohort and period on non-Hodgkin\'s lymphoma incidence and mortality were observed. In terms of prediction, future non-Hodgkin\'s lymphoma incidence and mortality in China will continue to increase, while the mortality rate will decrease; for women, both the rates are projected to rise, but they will remain lower than men.
    UNASSIGNED: Currently, the non-Hodgkin\'s lymphoma burden is high in China, and it is expected to continue increasing in the future. Policymakers need to prioritize addressing the factors contributing to sex differences in disease burden, including variations in environmental exposures and lifestyles among men and women.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    治疗相关的骨髓性肿瘤(t-MN)是自体外周血干细胞(PBSC)移植治疗非霍奇金淋巴瘤(NHL)的一种危及生命的并发症。先前的研究报告了PBSC中的克隆造血(CH)与t-MN风险之间的关联,但是小样本排除了特定亚群的风险检查。
    从984例NHL患者的回顾性队列中进行靶向DNA测序以鉴定PBSC中的CH突变(移植年龄为57岁;范围:18-78岁)。精细-灰色比例子分布风险回归模型估计CH突变数量与t-MN之间的关联,适应人口统计,临床,和治疗变量。次要分析评估了男性和女性中CH和t-MN之间的关联。
    在366名患者(37.2%)的PBSC中发现了CH。中位随访5y后,60例患者出现t-MN。存在≥2个突变会增加t-MN风险(调整后的风险比[aHR]=2.10,95%置信区间[CI]=1.08-4.11,p=0.029)。男性(aHR=1.83,95CI=1.01-3.31)中,女性(aHR=0.56,95CI=0.15-2.09)中,CH与t-MN风险增加相关。尽管PBSC中CH突变的患病率和类型相当,男性与男性相比,t-MN的8y累积发病率较高。女性患有CH(12.4%vs.3.6%),但在没有CH的男性和女性之间相似(4.9%与3.9%)。仅在雄性中观察到CH克隆从PBSC扩展到t-MN。
    在男性而非女性NHL患者中,PBSC中CH突变的存在增加了自体移植后t-MN的风险。基于性别的CH进展为t-MN风险差异的潜在因素值得进一步研究。
    UNASSIGNED: Therapy-related myeloid neoplasm (t-MN) is a life-threatening complication of autologous peripheral blood stem cell (PBSC) transplantation for non-Hodgkin lymphoma (NHL). Prior studies report an association between clonal hematopoiesis (CH) in PBSC and risk of t-MN, but small samples precluded examination of risk within specific sub-populations.
    UNASSIGNED: Targeted DNA sequencing was performed to identify CH mutations in PBSC from a retrospective cohort of 984 NHL patients (median age at transplant 57y; range: 18-78). Fine-Gray proportional subdistribution hazard regression models estimated association between number of CH mutations and t-MN, adjusting for demographic, clinical, and therapeutic variables. Secondary analyses evaluated association between CH and t-MN among males and females.
    UNASSIGNED: CH was identified in PBSC from 366 patients (37.2%). t-MN developed in 60 patients after median follow-up of 5y. Presence of ≥2 mutations conferred increased t-MN risk (adjusted hazard ratio [aHR]=2.10, 95% confidence interval [CI]=1.08-4.11, p=0.029). CH was associated with increased t-MN risk among males (aHR=1.83, 95%CI=1.01-3.31) but not females (aHR=0.56, 95%CI=0.15-2.09). Although prevalence and type of CH mutations in PBSC was comparable, the 8y cumulative incidence of t-MN was higher among males vs. females with CH (12.4% vs. 3.6%) but was similar between males and females without CH (4.9% vs. 3.9%). Expansion of CH clones from PBSC to t-MN was seen only among males.
    UNASSIGNED: Presence of CH mutations in PBSC confers increased risk of t-MN after autologous transplantation in male but not female patients with NHL. Factors underlying sex-based differences in risk of CH progression to t-MN merit further investigation.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Case Reports
    由舌头引起的粘膜相关淋巴组织(MALT)淋巴瘤是一种罕见的病理状况,尚未建立标准的治疗模式。这种疾病是一种低度淋巴瘤,常见于胃部,但很少见于舌头的淋巴组织。只有6个已报告的病例可以检索。我们介绍了一名79岁妇女的情况,她的舌头上有肿块。肿块的活检证实了MALT淋巴瘤的诊断。进行了17个部分的30.6Gy的放射治疗,并实现了完整的代谢反应。
    Mucosa-associated lymphoid tissue (MALT) lymphoma arising from the tongue is a rare pathologic condition for which a standard treatment mode has not been established. This disease represents a low-grade lymphoma frequently found in the stomach but rarely in the lymphoid tissue of the tongue. Only six cases that have been reported could be retrieved. We present the case of a 79-year-old woman who manifested with a mass on her tongue. A biopsy of the mass confirmed a diagnosis of MALT lymphoma. Radiation therapy of 30.6 Gy in 17 fractions was performed, and a complete metabolic response was achieved.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    非霍奇金淋巴瘤(NHL)包括由B细胞引起的各种恶性肿瘤,T细胞,和处于不同分化阶段的自然杀伤(NK)细胞。相反,经典霍奇金淋巴瘤(cHLs)主要以Reed-Sternberg细胞(RSC)为特征,背景是反应性免疫细胞。免疫调节途径,特别是PD-1/PD-L1轴,在NHL和cHL的肿瘤免疫逃避中起关键作用。在一系列淋巴瘤中观察到PD-1和PD-L1的表达升高,影响预后和治疗反应。治疗学上,针对PD-1/PD-L1的免疫检查点抑制剂(ICIs)彻底改变了淋巴瘤的管理,特别是复发/难治性病例。Nivolumab和pembrolizumab,其中,在各种B细胞淋巴瘤中表现出疗效,在cHL中有希望的结果。将ICI与常规化疗或靶向药物结合使用的联合策略显示出增强的疗效,并且正在进行广泛的探索。在这篇综述中,我们讨论了NHL和cHL的肿瘤微环境的最重要特征,用ICI解决治疗方法,并尝试概述未来的前景。
    Non-Hodgkin lymphomas (NHLs) encompass a diverse group of malignancies arising from B cells, T cells, and natural killer (NK) cells at various stages of differentiation. Conversely, classical Hodgkin lymphomas (cHLs) primarily feature Reed-Sternberg cells (RSCs) amid a background of reactive immune cells. Immunomodulatory pathways, notably the PD-1/PD-L1 axis, play pivotal roles in tumor immune evasion across both NHLs and cHLs. Elevated expression of PD-1 and PD-L1 is observed in a spectrum of lymphomas, influencing prognosis and treatment response. Therapeutically, immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 have revolutionized lymphoma management, particularly in relapsed/refractory cases. Nivolumab and pembrolizumab, among others, have demonstrated efficacy in various B-cell lymphomas, with promising outcomes in cHL. Combination strategies incorporating ICIs with conventional chemotherapy or targeted agents show enhanced efficacy and are being explored extensively. In this review we discuss the most important features of the tumor microenvironment of NHLs and cHLs, address the therapeutic approaches with ICIs and try to outline future perspectives.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

公众号